On 3 February, Caterpillar Inc. (NYSE:CAT) announced the center-pivot model lineup at World of Concrete in Las Vegas with the unveiling of the 420F2 IT. The 415F2, 416F2 and 430F2 round out the lineup. On Wednesday shares of Caterpillar Inc. (NYSE:CAT) closed at $81.95. Company’s sales growth for last 5 years was 11.20% and EPS growth for next 5 years is recorded as 9.69%.
Denbury Resources Inc. (NYSE:DNR) had its price objective cut by Barclays from $8.00 to $5.00 in a report released on Wednesday. Barclays currently has an equal weight rating on the stock. Denbury Resources Inc. (NYSE:DNR) in last trading activity decreased -4.99% to close at $8.19. Company weekly performance is 26.58% while its quarterly performance stands at -32.03%. Denbury Resources Inc. (NYSE:DNR) is -55.48% away from its 52 week high.
On 26 January, Genesco Inc. (NYSE:GCO) said that it has selected DiCentral to help streamline the company’s supply chain management processes and provide better exchanges of data with suppliers. Genesco selected DiConnect™ Enterprise as its EDI (EDI/INT) solution. In addition to connecting with the DiCentral Network, Genesco also plans to use DiConnect to exchange data with its large suppliers. On last trading day Genesco Inc. (NYSE:GCO) increased 0.06% to close at $71.96. Its volatility for the week is 2.72% while volatility for the month is 2.84%. GCO’s sales growth for past 5 years was 10.80% and its EPS growth for past 5 years was 24.60%. Genesco Inc. (NYSE:GCO) monthly performance is -6.61%.
Calamos Asset Management Inc. (NASDAQ:CLMS) announced a cash dividend. Payment of $0.15 per share is scheduled to be paid on February 23, 2015. Shareholders who purchased CLMS stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 3rd quarter that CLMS has paid the same dividend. Calamos Asset Management Inc. (NASDAQ:CLMS) has 0.60% insider ownership while its institutional ownership stands at 62.50%. In last trading activity company’s stock closed at $12.82.
Amgen Inc. (NASDAQ:AMGN) announced encouraging results from a phase III study on its biosimilar candidate ABP 501. The study is evaluating the efficacy and safety of ABP 501 in comparison to AbbVie Inc.’s Humira in adults suffering from moderate-to-severe plaque psoriasis. On last trading day Amgen Inc. (NASDAQ:AMGN) decreased -0.51% to close at $151.45. Its volatility for the week is 3.15% while volatility for the month is 3.16%. AMGN’s sales growth for past 5 years was 4.50% and its EPS growth for past 5 years was 12.00%. Amgen Inc. (NASDAQ:AMGN) monthly performance is -4.14%.